thiotepa 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antineoplastics, thiotepa derivatives	2638	52-24-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: thio-tepa triethylenethiophosphortriamide thiotepa oncotepa phosphorothioic acid triethylenetriamide tespamin tespamine thiophosphamide tepadina	A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed). Molecular weight: 189.22 Formula: C6H12N3PS CLOGP: 0.52 LIPINSKI: 0 HAC: 3 HDO: 0 TPSA: 9.03 ALOGS: -1.31 ROTB: 3 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

thio-tepa
triethylenethiophosphortriamide
thiotepa
oncotepa
phosphorothioic acid triethylenetriamide
tespamin
tespamine
thiophosphamide
tepadina

A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).

Molecular weight: 189.22
Formula: C6H12N3PS
CLOGP: 0.52
LIPINSKI: 0
HAC: 3
HDO: 0
TPSA: 9.03
ALOGS: -1.31
ROTB: 3

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Hosey CM, Chan R, Benet LZ
Vd (Volume of distribution)	1.60 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	6.70 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.90 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	2.70 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company
March 26, 2019	PMDA	Sumitomo Dainippon Pharma
March 26, 2021	EMA	RIEMSER Pharma GmbH
March 9, 1959	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Mucosal inflammation	407.64	38.97	157	5502	39985	50559480
Acute graft versus host disease	400.18	38.97	92	5567	3866	50595599
Human herpesvirus 6 infection	370.06	38.97	80	5579	2526	50596939
Cytomegalovirus infection	329.36	38.97	109	5550	17853	50581612
Graft versus host disease in skin	234.83	38.97	55	5604	2501	50596964
Chronic graft versus host disease	223.41	38.97	54	5605	2813	50596652
Venoocclusive liver disease	206.92	38.97	55	5604	4206	50595259
Acute graft versus host disease in skin	195.47	38.97	49	5610	2969	50596496
Encephalitis viral	193.15	38.97	43	5616	1554	50597911
Graft versus host disease	191.20	38.97	56	5603	6110	50593355
Febrile neutropenia	184.44	38.97	122	5537	97545	50501920
Product use in unapproved indication	183.99	38.97	130	5529	115689	50483776
Haematotoxicity	181.72	38.97	57	5602	7838	50591627
Pre-engraftment immune reaction	173.92	38.97	29	5630	209	50599256
Adenovirus infection	173.53	38.97	45	5614	3123	50596342
Cytomegalovirus infection reactivation	171.80	38.97	43	5616	2588	50596877
Cytomegalovirus viraemia	160.33	38.97	46	5613	4663	50594802
Thrombotic microangiopathy	139.82	38.97	48	5611	8743	50590722
Graft versus host disease in gastrointestinal tract	126.02	38.97	34	5625	2747	50596718
Bacterial sepsis	112.80	38.97	33	5626	3579	50595886
Acute graft versus host disease in intestine	108.05	38.97	27	5632	1612	50597853
Acute lymphocytic leukaemia recurrent	98.26	38.97	26	5633	1949	50597516
Neutropenia	97.07	38.97	100	5559	147865	50451600
Transplant dysfunction	92.04	38.97	30	5629	4654	50594811
Epstein-Barr virus infection	91.36	38.97	33	5626	6964	50592501
Thrombocytopenia	90.49	38.97	90	5569	127583	50471882
Venoocclusive disease	89.76	38.97	24	5635	1872	50597593
Posterior reversible encephalopathy syndrome	88.86	38.97	40	5619	14888	50584577
BK virus infection	75.54	38.97	23	5636	2858	50596607
Sepsis	73.30	38.97	82	5577	132843	50466622
Neurotoxicity	70.65	38.97	34	5625	14706	50584759
Viral haemorrhagic cystitis	69.38	38.97	16	5643	677	50598788
Transplant failure	67.17	38.97	18	5641	1415	50598050
Cystitis haemorrhagic	65.86	38.97	22	5637	3680	50595785
Neoplasm recurrence	62.48	38.97	19	5640	2350	50597115
Meningoencephalitis herpetic	62.44	38.97	16	5643	1056	50598409
Toxic erythema of chemotherapy	61.37	38.97	11	5648	126	50599339
Bacteraemia	59.36	38.97	30	5629	14403	50585062
Cytomegalovirus chorioretinitis	57.04	38.97	16	5643	1491	50597974
Hypogonadism female	56.70	38.97	8	5651	14	50599451
Post transplant lymphoproliferative disorder	55.51	38.97	20	5639	4184	50595281
Progressive multifocal leukoencephalopathy	53.60	38.97	26	5633	11431	50588034
Pyrexia	52.93	38.97	125	5534	380078	50219387
Viraemia	52.74	38.97	14	5645	1061	50598404
Multiple organ dysfunction syndrome	52.24	38.97	44	5615	50293	50549172
Fatigue	51.00	38.97	9	5650	707592	49891873
Off label use	47.62	38.97	138	5521	474288	50125177
Stem cell transplant	46.66	38.97	14	5645	1654	50597811
Leukaemia recurrent	46.04	38.97	13	5646	1241	50598224
Leukoencephalopathy	45.80	38.97	17	5642	3866	50595599
Pulmonary vascular disorder	45.34	38.97	10	5649	345	50599120
Pulmonary arterial hypertension	44.65	38.97	28	5631	20291	50579174
Alveolar soft part sarcoma	44.06	38.97	8	5651	99	50599366
Dyspnoea	43.99	38.97	5	5654	547603	50051862
Osteosarcoma	42.57	38.97	8	5651	121	50599344
Skin toxicity	42.04	38.97	16	5643	3897	50595568
Lower respiratory tract infection fungal	41.52	38.97	9	5650	286	50599179
JC virus infection	41.29	38.97	13	5646	1802	50597663
Polyomavirus-associated nephropathy	39.02	38.97	12	5647	1540	50597925

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Mucosal inflammation	425.90	33.66	185	6526	31410	29536406
Cytomegalovirus infection	365.95	33.66	152	6559	23063	29544753
Acute graft versus host disease	330.35	33.66	99	6612	5725	29562091
Acute graft versus host disease in skin	315.99	33.66	91	6620	4573	29563243
Acute graft versus host disease in intestine	243.49	33.66	64	6647	2277	29565539
Human herpesvirus 6 infection	242.98	33.66	61	6650	1802	29566014
Venoocclusive liver disease	240.48	33.66	81	6630	6836	29560980
Graft versus host disease in skin	224.67	33.66	65	6646	3314	29564502
Adenovirus infection	207.06	33.66	65	6646	4382	29563434
Graft versus host disease in gastrointestinal tract	187.30	33.66	56	6655	3202	29564614
Febrile neutropenia	166.47	33.66	163	6548	112077	29455739
Epstein-Barr virus infection	159.24	33.66	59	6652	6570	29561246
Cytomegalovirus infection reactivation	155.87	33.66	49	6662	3315	29564501
Chronic graft versus host disease	147.18	33.66	49	6662	3980	29563836
Graft versus host disease	131.32	33.66	57	6654	9571	29558245
Venoocclusive disease	130.30	33.66	40	6671	2499	29565317
Haematotoxicity	122.87	33.66	49	6662	6650	29561166
Product use in unapproved indication	119.04	33.66	121	6590	86754	29481062
Pulmonary vascular disorder	96.05	33.66	23	6688	554	29567262
Viral haemorrhagic cystitis	94.36	33.66	25	6686	915	29566901
Pulmonary arterial hypertension	91.54	33.66	41	6670	7408	29560408
Cystitis haemorrhagic	90.81	33.66	36	6675	4806	29563010
Cytomegalovirus viraemia	88.06	33.66	38	6673	6282	29561534
Post transplant lymphoproliferative disorder	86.41	33.66	36	6675	5457	29562359
Thrombotic microangiopathy	85.54	33.66	41	6670	8640	29559176
Posterior reversible encephalopathy syndrome	81.24	33.66	40	6671	8936	29558880
Engraftment syndrome	77.89	33.66	21	6690	822	29566994
Encephalitis viral	71.77	33.66	21	6690	1111	29566705
BK virus infection	71.19	33.66	30	6681	4677	29563139
Pulmonary arteriopathy	71.11	33.66	13	6698	76	29567740
Autoimmune lymphoproliferative syndrome	68.90	33.66	14	6697	152	29567664
Graft versus host disease in liver	68.20	33.66	20	6691	1066	29566750
Parainfluenzae virus infection	65.14	33.66	23	6688	2226	29565590
Thrombocytopenia	64.43	33.66	112	6599	134711	29433105
Multiple organ dysfunction syndrome	63.77	33.66	75	6636	63041	29504775
Juvenile melanoma benign	59.23	33.66	11	6700	71	29567745
Off label use	57.93	33.66	174	6537	300626	29267190
Pre-engraftment immune reaction	57.16	33.66	11	6700	88	29567728
Cytomegalovirus chorioretinitis	53.55	33.66	22	6689	3216	29564600
Chronic graft versus host disease in skin	50.99	33.66	15	6696	808	29567008
Pneumonia cytomegaloviral	50.48	33.66	20	6691	2662	29565154
Myelitis transverse	48.64	33.66	15	6696	950	29566866
Acute graft versus host disease in liver	47.76	33.66	16	6695	1322	29566494
Idiopathic pneumonia syndrome	47.18	33.66	11	6700	235	29567581
Autoimmune haemolytic anaemia	46.69	33.66	21	6690	3827	29563989
Fatigue	46.63	33.66	8	6703	316813	29251003
Neutropenia	46.24	33.66	96	6615	131615	29436201
Bacterial sepsis	45.67	33.66	22	6689	4681	29563135
Bronchiolitis obliterans syndrome	45.62	33.66	10	6701	160	29567656
Respiratory syncytial virus infection	44.49	33.66	20	6691	3639	29564177
Sepsis	44.36	33.66	99	6612	142583	29425233
Osteosarcoma	43.86	33.66	10	6701	193	29567623
NPM1 gene mutation	42.80	33.66	9	6702	117	29567699
Dyspnoea	42.45	33.66	11	6700	326721	29241095
CNS ventriculitis	42.44	33.66	10	6701	224	29567592
Bone marrow failure	40.70	33.66	40	6671	27409	29540407
Encephalitis cytomegalovirus	39.57	33.66	11	6700	483	29567333
Aplasia	39.43	33.66	19	6692	4044	29563772
Chimerism	37.37	33.66	9	6702	222	29567594
Bone sarcoma	35.06	33.66	7	6704	69	29567747
Leukoencephalopathy	34.71	33.66	17	6694	3750	29564066
Angiodysplasia	34.62	33.66	10	6701	505	29567311

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cytomegalovirus infection	742.52	30.04	274	11785	36925	64449748
Mucosal inflammation	678.62	30.04	297	11762	62287	64424386
Acute graft versus host disease in skin	648.69	30.04	167	11892	6688	64479985
Acute graft versus host disease	583.73	30.04	163	11896	8921	64477752
Human herpesvirus 6 infection	547.61	30.04	135	11924	4519	64482154
Graft versus host disease in skin	451.33	30.04	119	11940	5228	64481445
Venoocclusive liver disease	436.58	30.04	133	11926	9882	64476791
Adenovirus infection	428.86	30.04	122	11937	7133	64479540
Acute graft versus host disease in intestine	385.97	30.04	97	11962	3512	64483161
Febrile neutropenia	356.06	30.04	288	11771	187369	64299304
Cytomegalovirus infection reactivation	341.09	30.04	97	11962	5659	64481014
Graft versus host disease	332.30	30.04	117	11942	13696	64472977
Graft versus host disease in gastrointestinal tract	307.58	30.04	89	11970	5523	64481150
Product use in unapproved indication	301.33	30.04	255	11804	176363	64310310
Haematotoxicity	294.11	30.04	105	11954	12791	64473882
Epstein-Barr virus infection	282.23	30.04	101	11958	12387	64474286
Chronic graft versus host disease	267.68	30.04	82	11977	6194	64480479
Encephalitis viral	254.60	30.04	64	11995	2316	64484357
Venoocclusive disease	244.40	30.04	69	11990	3916	64482757
Cytomegalovirus viraemia	238.74	30.04	86	11973	10742	64475931
Pre-engraftment immune reaction	217.79	30.04	40	12019	301	64486372
Thrombotic microangiopathy	196.16	30.04	84	11975	16571	64470102
Viral haemorrhagic cystitis	170.08	30.04	43	12016	1592	64485081
BK virus infection	163.85	30.04	59	12000	7353	64479320
Bacterial sepsis	159.76	30.04	58	12001	7399	64479274
Cystitis haemorrhagic	148.79	30.04	56	12003	7900	64478773
Pulmonary vascular disorder	140.37	30.04	33	12026	896	64485777
Posterior reversible encephalopathy syndrome	135.55	30.04	72	11987	22874	64463799
Post transplant lymphoproliferative disorder	135.46	30.04	55	12004	9489	64477184
Pulmonary arterial hypertension	120.66	30.04	69	11990	25298	64461375
Multiple organ dysfunction syndrome	106.25	30.04	112	11947	101301	64385372
Sepsis	105.78	30.04	169	11890	230172	64256501
Chronic graft versus host disease in skin	103.30	30.04	28	12031	1363	64485310
Fatigue	101.70	30.04	11	12048	748719	63737954
Engraftment syndrome	99.76	30.04	26	12033	1087	64485586
Autoimmune haemolytic anaemia	97.75	30.04	40	12019	7036	64479637
Transplant dysfunction	96.36	30.04	39	12020	6669	64480004
Acute lymphocytic leukaemia recurrent	96.35	30.04	34	12025	3992	64482681
Off label use	94.15	30.04	295	11764	632511	63854162
Thrombocytopenia	93.00	30.04	157	11902	223644	64263029
Pulmonary arteriopathy	90.83	30.04	16	12043	92	64486581
Dyspnoea	89.31	30.04	14	12045	718660	63768013
Neutropenia	89.03	30.04	160	11899	239464	64247209
Osteosarcoma	85.60	30.04	18	12041	288	64486385
Acute graft versus host disease in liver	80.31	30.04	24	12035	1663	64485010
Respiratory syncytial virus infection	80.11	30.04	35	12024	7233	64479440
Cytomegalovirus chorioretinitis	79.05	30.04	31	12028	4881	64481792
Transplant failure	72.00	30.04	27	12032	3767	64482906
Autoimmune lymphoproliferative syndrome	70.09	30.04	14	12045	171	64486502
Arthralgia	70.00	30.04	3	12056	442257	64044416
Leukoencephalopathy	68.60	30.04	31	12028	6936	64479737
Neoplasm recurrence	65.15	30.04	25	12034	3714	64482959
Graft versus host disease in liver	65.11	30.04	20	12039	1521	64485152
Pneumonia cytomegaloviral	64.99	30.04	26	12033	4313	64482360
Pyrexia	64.89	30.04	240	11819	558404	63928269
Neurotoxicity	64.59	30.04	48	12011	27356	64459317
Metaplasia	64.12	30.04	15	12044	398	64486275
Parainfluenzae virus infection	62.75	30.04	26	12033	4717	64481956
Focal nodular hyperplasia	62.05	30.04	16	12043	641	64486032
Pain	61.82	30.04	14	12045	553497	63933176
Skin toxicity	60.67	30.04	28	12031	6574	64480099
Myelitis transverse	59.92	30.04	19	12040	1604	64485069
Stem cell transplant	59.67	30.04	23	12036	3458	64483215
Dizziness	59.08	30.04	6	12053	430157	64056516
Leukaemia recurrent	58.63	30.04	21	12038	2573	64484100
Epstein-Barr viraemia	58.02	30.04	19	12040	1778	64484895
Bone marrow failure	57.49	30.04	57	12002	47895	64438778
Toxic erythema of chemotherapy	55.52	30.04	12	12047	220	64486453
Meningoencephalitis herpetic	54.37	30.04	18	12041	1743	64484930
Bacteraemia	54.35	30.04	43	12016	26868	64459805
Hepatotoxicity	52.59	30.04	50	12009	39912	64446761
Hypogonadism female	52.59	30.04	8	12051	14	64486659
Aplasia	50.24	30.04	25	12034	6928	64479745
Rhinovirus infection	50.07	30.04	24	12035	6132	64480541
Idiopathic pneumonia syndrome	50.05	30.04	13	12046	536	64486137
NPM1 gene mutation	49.49	30.04	10	12049	130	64486543
Bronchiolitis obliterans syndrome	48.53	30.04	11	12048	253	64486420
Gastroenteritis adenovirus	48.32	30.04	11	12048	258	64486415
Mucosal toxicity	46.55	30.04	12	12047	480	64486193
Bone sarcoma	46.52	30.04	9	12050	92	64486581
Viraemia	45.60	30.04	17	12042	2332	64484341
Toxoplasmosis	44.95	30.04	17	12042	2427	64484246
Pruritus	43.81	30.04	4	12055	312396	64174277
Nausea	43.42	30.04	50	12009	785750	63700923
Chimerism	42.72	30.04	10	12049	266	64486407
Disseminated toxoplasmosis	42.56	30.04	9	12050	148	64486525
Encephalitis cytomegalovirus	42.27	30.04	13	12046	992	64485681
Pulmonary veno-occlusive disease	41.71	30.04	14	12045	1414	64485259
Multisystem inflammatory syndrome in children	40.56	30.04	7	12052	35	64486638
Headache	39.82	30.04	25	12034	529442	63957231
Second primary malignancy	39.31	30.04	26	12033	12311	64474362
Herpes simplex reactivation	37.48	30.04	9	12050	268	64486405
Malaise	36.91	30.04	14	12045	396233	64090440
Asthenia	36.86	30.04	17	12042	428027	64058646
Premature menopause	35.99	30.04	10	12049	534	64486139
Acute myeloid leukaemia recurrent	35.94	30.04	15	12044	2769	64483904
Herpes simplex	35.51	30.04	23	12036	10513	64476160
Bacille Calmette-Guerin scar reactivation	34.77	30.04	6	12053	30	64486643
Cerebral toxoplasmosis	34.66	30.04	13	12046	1813	64484860
Alveolar soft part sarcoma	34.50	30.04	7	12052	93	64486580
Myelodysplastic syndrome	33.45	30.04	33	12026	27546	64459127
Pneumocystis jirovecii pneumonia	33.39	30.04	33	12026	27601	64459072
Acute respiratory distress syndrome	32.12	30.04	38	12021	38897	64447776
Angiodysplasia	31.83	30.04	10	12049	819	64485854
Chronic graft versus host disease in intestine	31.82	30.04	8	12051	289	64486384
Pain in extremity	31.20	30.04	9	12050	303076	64183597
Chronic graft versus host disease in liver	31.02	30.04	9	12050	562	64486111
CNS ventriculitis	30.68	30.04	8	12051	335	64486338
Weight decreased	30.32	30.04	8	12051	285731	64200942
Condition aggravated	30.22	30.04	16	12043	372410	64114263

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01AC01	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS ALKYLATING AGENTS Ethylene imines
FDA MoA	N0000000236	Alkylating Activity
FDA EPC	N0000175558	Alkylating Drug
MeSH PA	D000477	Alkylating Agents
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D018906	Antineoplastic Agents, Alkylating
MeSH PA	D007155	Immunologic Factors
MeSH PA	D007166	Immunosuppressive Agents
MeSH PA	D019653	Myeloablative Agonists
MeSH PA	D009676	Noxae

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Allogeneic bone marrow transplantation	indication	58390007
Hodgkin's disease	indication	118599009
Malignant lymphoma	indication	118600007	DOID:0060058
Non-Hodgkin's lymphoma	indication	118601006
Malignant tumor of ovary	indication	363443007	DOID:2394
Malignant tumor of urinary bladder	indication	399326009	DOID:11054
Carcinoma of female breast	indication	447782002
Pleural Malignant Effusions	indication
Peritoneal Malignant Effusions	indication
Pericardial Malignant Effusions	indication
Acute infectious disease	contraindication	63171007
Blood coagulation disorder	contraindication	64779008	DOID:1247
Leukopenia	contraindication	84828003	DOID:615
Kidney disease	contraindication	90708001	DOID:557
Disease of liver	contraindication	235856003	DOID:409
Anemia	contraindication	271737000	DOID:2355
Pregnancy, function	contraindication	289908002
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Bone marrow depression	contraindication	307762000
Breastfeeding (mother)	contraindication	413712001

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
100MG/VIAL	TEPADINA	ADIENNE SA	N208264	Jan. 26, 2017	RX	POWDER	INTRACAVITARY, INTRAVENOUS, INTRAVESICAL	Jan. 26, 2024	INDICATED FOR REDUCING THE RISK OF GRAFT REJECTION WHEN USED IN CONJUNCTION WITH HIGH-DOSE BUSULFAN & CYCLOPHOSPHAMIDE AS A PREPARATIVE REGIMEN FOR ALLOGENIC HEMATOPOIETIC PROGENITOR CELL TRANSPLANTATION FOR PEDS. PATIENTS WITH CLASS 3 BETA-THALASSEMIA
15MG/VIAL	TEPADINA	ADIENNE SA	N208264	Jan. 26, 2017	RX	POWDER	INTRACAVITARY, INTRAVENOUS, INTRAVESICAL	Jan. 26, 2024	INDICATED FOR REDUCING THE RISK OF GRAFT REJECTION WHEN USED IN CONJUNCTION WITH HIGH-DOSE BUSULFAN & CYCLOPHOSPHAMIDE AS A PREPARATIVE REGIMEN FOR ALLOGENIC HEMATOPOIETIC PROGENITOR CELL TRANSPLANTATION FOR PEDS. PATIENTS WITH CLASS 3 BETA-THALASSEMIA

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Cytochrome P450 2B6	Enzyme	P20813	CP2B6_HUMAN	INHIBITOR	Ki	5.32		IUPHAR

External reference:

ID	Source
4017910	VUID
N0000146261	NUI
D00583	KEGG_DRUG
4017910	VANDF
C0039871	UMLSCUI
CHEBI:9570	CHEBI
CHEMBL671	ChEMBL_ID
D013852	MESH_DESCRIPTOR_UI
DB04572	DRUGBANK_ID
7622	IUPHAR_LIGAND_ID
881	INN_ID
905Z5W3GKH	UNII
5453	PUBCHEM_CID
10473	RXNORM
184712	MMSL
2134	MMSL
5573	MMSL
d00390	MMSL
002637	NDDF
387508004	SNOMEDCT_US
88997008	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Thiotepa	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9309	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	15 mg	INTRACAVITARY	ANDA	22 sections
Thiotepa	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9565	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	15 mg	INTRACAVITARY	ANDA	22 sections
Thiotepa	HUMAN PRESCRIPTION DRUG LABEL	1	25021-246	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	15 mg	INTRAVENOUS	ANDA	23 sections
Thiotepa	HUMAN PRESCRIPTION DRUG LABEL	1	43598-650	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	15 mg	INTRAVENOUS	ANDA	20 sections
Thiotepa	HUMAN PRESCRIPTION DRUG LABEL	1	54879-014	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	15 mg	INTRACAVITARY	ANDA	23 sections
Thiotepa	HUMAN PRESCRIPTION DRUG LABEL	1	65219-029	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	100 mg	INTRAVENOUS	ANDA	27 sections
Thiotepa	Human Prescription Drug Label	1	68083-446	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	15 mg	INTRAVENOUS	ANDA	27 sections
Thiotepa	Human Prescription Drug Label	1	68083-503	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	100 mg	INTRAVENOUS	ANDA	27 sections
Thiotepa	Human Prescription Drug Label	1	69539-123	INJECTION, POWDER, FOR SOLUTION	15 mg	INTRAVENOUS	ANDA	25 sections
Thiotepa	Human Prescription Drug Label	1	69539-124	INJECTION, POWDER, FOR SOLUTION	100 mg	INTRAVENOUS	ANDA	25 sections
TEPADINA	HUMAN PRESCRIPTION DRUG LABEL	1	70121-1630	INJECTION, POWDER, FOR SOLUTION	15 mg	INTRACAVITARY	NDA	18 sections
TEPADINA	HUMAN PRESCRIPTION DRUG LABEL	1	70121-1630	INJECTION, POWDER, FOR SOLUTION	15 mg	INTRACAVITARY	NDA	18 sections
TEPADINA	HUMAN PRESCRIPTION DRUG LABEL	1	70121-1631	INJECTION, POWDER, FOR SOLUTION	100 mg	INTRACAVITARY	NDA	18 sections
TEPADINA	HUMAN PRESCRIPTION DRUG LABEL	1	70121-1631	INJECTION, POWDER, FOR SOLUTION	100 mg	INTRACAVITARY	NDA	18 sections
Thiotepa	Human Prescription Drug Label	1	72205-045	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	15 mg	INTRAVENOUS	ANDA	25 sections
Thiotepa	Human Prescription Drug Label	1	72205-046	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	100 mg	INTRAVENOUS	ANDA	25 sections